Bacterial toxins as versatile delivery vehicles

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 2, 2002, Pages 269-278

  De Haan, Lolke ^a   Hirst, Timothy R ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Antigen presentation; Antiviral and anticancer vaccines; Class I epitopes; Immunomodulation; Protein and DNA delivery

Indexed keywords

ADENYLATE CYCLASE; ANTHRAX TOXIN; BACTERIAL TOXIN; CANCER VACCINE; CHOLERA TOXIN; DIPHTHERIA TOXIN; DNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERTUSSIS TOXIN; PSEUDOMONAS EXOTOXIN; SHIGA TOXIN; VEROTOXIN; VIRUS VACCINE;

ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CELL COMPARTMENTALIZATION; CYTOSOL; DRUG DELIVERY SYSTEM; GENE TARGETING; INFLAMMATION; LYSOSOME; MACROMOLECULE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN INTERACTION; REVIEW;

ANIMALS; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASES; BACTERIAL TOXINS; DNA; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENES, MHC CLASS I; HUMANS; VEHICLES;

EID: 0036489771     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Understanding the mode of action of diphtheria toxin: A perspective on progress during the 20th century
2. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems
3. Recent developments in bacterial conjugate vaccines
4. Worldwide Haemophilus influenzae type B disease at the beginning of the 21st century: Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates
5. Oral tolerance and antipathological vaccines
6. Immune modulation by the cholera-like enterotoxins: From adjuvant to therapeutic
7. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins
8. Cut and trim: Generating MHC class I peptide ligands
9. Class II antigen processing: Analysis of compartments and functions
10. Peptides fused to the amino-terminal end of diphtheria toxin are translocated to the cytosol
11. Toxins of Bacillus anthracis
12. Identification of the cellular receptor for anthrax toxin
13. Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides
14. Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells
15. Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo
16. Anthrax toxin as a molecular tool for stimulation of cytotoxic T lymphocytes: Disulfide-linked epitopes, multiple injections, and role of CD4+ cells
17. Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity
18. Anthrax toxin-mediated delivery in vivo and in vitro of a cytotoxic T-lymphocyte epitope from ovalbumin
19. Induction of hepatitis C virus-specific cytotoxic T-lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein
20. Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T-cell immunity
21. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein
22. Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol
23. Bordetella pertussis adenylate cyclase: A toxin with multiple talents
24. Cell-invasive activity of epitope-tagged adenylate cyclase of Bordetella pertussis allows in vitro presentation of a foreign epitope to CD8+ cytotoxic T-cells
25. Direct delivery of the Bordetella pertussis adenylate cyclase toxin to the MHC class I antigen presentation pathway
26. Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T-cell epitope from lymphocytic choriomeningitis virus
27. Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T-cell epitope
28. In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying multiple copies of a viral CD8+ T-cell epitope
29. In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T-cell epitopes
30. Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis
31. Delivery of CD8+ T-cell epitopes into major histocompatibility complex class I antigen presentation pathway by Bordetella pertussis adenylate cyclase: Delineation of cell invasive structures and permissive insertion sites
32. Charge-dependent translocation of Bordetella pertussis adenylate cyclase toxin into eukaryotic cells: Implication for the in vivo delivery of CD8+ T-cell epitopes into antigen-presenting cells
33. Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity
34. Characterization of recombinant Bordetella pertussis adenylate cyclase toxins carrying passenger proteins
35. Shiga toxins
36. Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway
37. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin
38. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens
39. Membrane traffic and the cellular uptake of cholera toxin
40. Cholera toxin and related enterotoxins: A cell biological and immunological perspective
41. Specific inhibition of herpes virus replication by receptor-mediated entry of an antiviral peptide linked to Escherichia coli enterotoxin B subunit
42. Intranuclear delivery of an antiviral peptide mediated by the B subunit of Escherichia coli heat-labile enterotoxin
43. Enhanced delivery of exogenous peptides into the class I antigen processing and presentation pathway
44. Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway
45. Stimulation of HIV gp120-specific cytolytic T-lymphocyte responses in vitro and in vivo using a detoxified pertussis toxin vector
46. Targeted delivery of peptide epitopes to class I major histocompatibility molecules by a modified Pseudomonas exotoxin
47. Presentation of an exogenous antigen by major histocompatibility complex class I molecules
48. Type III secretion machines: Bacterial devices for protein delivery into host cells
49. Delivery of epitopes by the Salmonella type III secretion system for vaccine development
50. Cholera toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance
51. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit
52. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes
53. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine
54. Prevention of autoimmune disease due to lymphocyte modulation by the B-subunit of Escherichia coli heat-labile enterotoxin
55. Cross-linking of cell surface ganglioside GM1 induces the selective apoptosis of mature CD8+ T-lymphocytes
56. Modulation of B-cell activation by the B subunit of Escherichia coli enterotoxin: Receptor interaction up-regulates MHC class II, B7, CD40, CD25 and ICAM-1
57. Cholera toxin and Escherichia coli enterotoxin B-subunits inhibit macrophage-mediated antigen processing and presentation: Evidence for antigen persistence in non-acidic recycling endosomal compartments
58. Oral administration of cholera toxin B subunit conjugated to myelin basic protein protects against experimental autoimmune encephalomyelitis by inducing transforming growth factor-β-secreting cells and suppressing chemokine expression
59. Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells
60. Gene therapy: Recombinant adeno-associated virus vectors
61. Gene transfer with herpes simplex vectors
62. Development of non-viral vectors for systemic gene delivery
63. Towards synthetic viruses
64. Fate of DNA targeted to the liver by asialoglycoprotein receptor-mediated endocytosis in vivo. Prolonged persistence in cytoplasmic vesicles after partial hepatectomy
65. The transmembrane domain of diphtheria toxin improves molecular conjugate gene transfer
66. Target cell-specific DNA transfer mediated by a chimeric multidomain protein. Novel nonviral gene delivery system
67. A modular DNA carrier protein based on the structure of diphtheria toxin mediates target cell-specific gene delivery
68. Development of DNA delivery system using Pseudomonas exotoxin A and a DNA binding region of human DNA topoisomerase I
69. 3 positive cells